In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections

Research in Veterinary Science

Volumn 77, Issue 1, 2004, Pages 67-71

  Ganière, Jean Pierre ^a   Médaille, Christine ^b   Etoré, Florence ^c  

^a LUNAM UNIVERSITÉ   (France)

^b LABORATOIRE VÉBIOTEL   (France)

^c Schering Plough   (France)

Author keywords

Dog; MIC; Orbifloxacin; Otitis; Pyoderma; Staphylococcus intermedius; Time kill kinetic

Indexed keywords

ORBIFLOXACIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG DISEASE; EAR INFECTION; FRANCE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PYODERMA; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INTERMEDIUS; TIME;

CANIS FAMILIARIS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INTERMEDIUS;

EID: 3042608379     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2004.02.002     Document Type: Article

References (24)

1. Asuquo, A.E., Piddock, L.J.V., 1993. Accumulation and killing kinetics of fifteen quinolones for Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 31, 865-880.
2. Brown, S.A., 1996. Fluoroquinolones in animal health. Journal of Veterinary Pharmacology and Therapeutics 19, 1-14.
3. Cester, C.C., Schneider, M., Toutain, P.L., 1996. Comparative kinetics of two orally administered fluoroquinolones in dogs: enrofloxacin versus marbofloxacin. Revue de Médecine Vé térinaire 147, 703-716.
4. Coelho-Baptista, B., Costa, M., Duarte-Correia, J., Pomba, C., 2003. In vitro activity of enrofloxacin, marbofloxacin, orbifloxacin and ciprofloxacin against clinical strains of Staphylococcus intermedius isolated from dogs in Portugal. Journal of Veterinary Pharmacology and Therapeutics 26 (Suppl. 1), 155-156.
5. Colombini, S., Merchant, S.R., Hosgood, G., 2000. Microbial flora and antimicrobial susceptibility patterns from dogs with otitis media. Veterinary Dermatology 11, 235-239.
6. Dowling, P.M., 1996. Antimicrobial therapy of skin and ear infections. Canadian Veterinary Journal 37, 695-699.
7. Dudley, M.N., 1991. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. American Journal of Medicine 91 (Suppl. 6A), 45-50.
8. Ganière, J.-P., Médaille, C., Limet, A., Ruvoen, N., Andre-Fontaine, G., 2001. Antimicrobial activity of enrofloxacin against Staphylococcus intermedius strains isolated from canine pyodermas. Veterinary Dermatology 12, 171-175.
9. Heinen, E., 2002. Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. Journal of Veterinary Pharmacology and Therapeutics 25, 1-5.
10. Hyatt, J.M., McKinnon, P.S., Zimmer, G.S., Schentag, J.J., 1995. The importance of pharmacokinetic/pharmacodynamic surrogate marker to outcome. Clinical Pharmacokinetic 28, 143-160.
11. Ihrke, P.J., 1987, An overview of bacterial skin disease in the dog. British Veterinary Journal 143, 112-118.
12. Ihrke, P.J., Papich, M.G., Demanuelle, T.C., 1999. The use of fluoroquinolones in veterinary dermatology. Veterinary Dermatology 10, 193-204.
13. Kay-Mugford, P.A., Weingarten, A.J., Ngoh, M., Zolynas, R., White, A., Katz, T., Simmons, R., Varma, K.J., 2002. Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma. Veterinary Therapeutics 3, 402-408.
14. Lloyd, D., Allaker, R.P., Pattinson, A.L., 1991. Carriage of Staphylococcus intermedius on the ventral abdomen of clinically normal dogs and those with pyoderma. Veterinary Dermatology 2, 161-164.
15. Lloyd, D.H., Lamport, A., Noble, C., Howell, S., 1999. Fluoroquinolone resistance in Staphylococcus intermedius. Veterinary Dermatology 10, 249-251.
16. Matsumoto, S., Takahashi, M., Yoshida, M., Komatsu, T., Kitadai, Y., Horii, Y., Katae, H., 1997. Absorption, distribution and excretion of orbifloxacin in dogs and cats. Journal of the Japanese Veterinary Medical Association 50, 470-474.
17. Meinen, J.B., Rosin, E., Macclure, J.T., 1995. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. American Journal of Veterinary Research 56, 1219-1224.
18. National Committee for Clinical Laboratory Standards, 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards, fourth ed. NCCLS Document M7-A4, Villanova, PA.
19. National Committee for Clinical Laboratory Standards, 2002. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard, second ed. NCCLS document M31-A2, Wayne, PA.
20. Petersen, A.D., Walker, R.D., Bowman, M.M., Schott, H.C., Rosser, E.J., 2002. Frequency of isolation and antimicrobial susceptibility patterns of Staphylococcus intermedius and Pseudomonas. aeruginosa isolates from canine skin and car samples over a 6-year period (1992-1997). Journal of the American Animal Hospital Association 38, 407-413.
21. Pirro, F., Edingloh, M., Schmeer, N., 1999. Bactericidal and inhibitory activity of enrofloxacin and other fluoroquinolones in small animal pathogens. Compendium on Continuing Education for the Practicing Veterinarian 21 (Suppl. 12M), 19-25.
22. Prescott, J.F., Hanna, W.J., Reid-Smith, R., Drost, K., 2002. Antimicrobial drug use and resistance in dogs. Canadian Veterinary Journal 43, 107-116.
23. Spreng, M., Deleforge, J., Thomas, V., Boisrame, B., Drugeon, H., 1995. Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates. Journal of Veterinary Pharmacology and Therapeutics 18, 284-289.
24. Wright, D.H., Brown, G.H., Peterson, M.L., Rotschafer, J.C., 2000. Application of fluoroquinolone pharmacodynamics. Journal of Antimicrobial Chemotherapy 46, 669-683.